Organization
Wuxi No.2 People’s Hospital
1 abstract
Abstract
A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2–negative advanced breast cancer.Org: Affiliated Hospital of Jiangnan University (Wuxi Fourth People's Hospital), Wuxi No.2 People’s Hospital, Jiangnan University Affiliated Hospital,